MedPath

Comparing Different Patterns of rTMS in Major Depression

Not Applicable
Conditions
Depression; Bipolar Disorder
Registration Number
NCT02778035
Lead Sponsor
University Health Network, Toronto
Brief Summary

This trial will compare the trajectories of improvement for three different patterns of twice-daily rTMS in major depression: two daily sessions of dorsomedial prefrontal rTMS delivered at 0 min vs. 30 min vs. 60 min intervals.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
180
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
17-Item Hamilton Rating Scale for Depression (HAMD-17)Baseline, after each week of treatment (i.e. after 5 days of treatment), and 1, 4, and 12 weeks post-treatment. Treatment will include 5 daily weekday visits over 4 weeks (20 sessions total).

Outcome measured by a change in HAMD-17 score from baseline to 1-week post-treatment. A 50% improvement in the score is considered a response to rTMS. A final score of ≤7 is categorized as remission.

Secondary Outcome Measures
NameTimeMethod
Beck Depression Inventory-II (BDI-II)Daily for 4 weeks, 5 days per week, in addition to three follow-up visits at 1, 4, and 12 weeks post-treatment

Outcome measured by a change in BDI-II score from baseline to 1-week post-treatment. A 50% improvement in the score is considered a response to rTMS. A final score of ≤12 is categorized as remission.

Trial Locations

Locations (2)

UHN MRI-Guided rTMS Clinic, Toronto Western Hospital

🇨🇦

Toronto, Ontario, Canada

Centre for Addiction and Mental Health

🇨🇦

Toronto, Ontario, Canada

UHN MRI-Guided rTMS Clinic, Toronto Western Hospital
🇨🇦Toronto, Ontario, Canada
Laura Schulze
Contact
416-603-5667
laura.schulze@uhn.ca
Terri Cairo
Contact
416-603-5667
terri.cairo@uhn.ca
Jonathan Downar, MD PhD FRCPC
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.